These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15377746)

  • 1. Fluvoxamine treatment of major depression associated with multiple sclerosis.
    Benedetti F; Campori E; Colombo C; Smeraldi E
    J Neuropsychiatry Clin Neurosci; 2004; 16(3):364-6. PubMed ID: 15377746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder.
    Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
    Am J Psychiatry; 2004 Nov; 161(11):2060-5. PubMed ID: 15514407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mild case of serotonin syndrome?
    McIntosh D
    Can J Psychiatry; 2000 Aug; 45(6):571-2. PubMed ID: 10986578
    [No Abstract]   [Full Text] [Related]  

  • 5. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis.
    Rausch JL; Hobby HM; Shendarkar N; Johnson ME; Li J
    J Clin Psychopharmacol; 2001 Apr; 21(2):139-42. PubMed ID: 11270909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
    Sato K; Yoshida K; Takahashi H; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Neuropsychobiology; 2002; 46(3):136-40. PubMed ID: 12422060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine.
    Ito K; Yoshida K; Sato K; Takahashi H; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Psychiatry Res; 2002 Aug; 111(2-3):235-9. PubMed ID: 12374640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
    Dalery J; Honig A
    Hum Psychopharmacol; 2003 Jul; 18(5):379-84. PubMed ID: 12858325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine in the treatment of late-life depression: how much we know coming from randomized controlled trials: comment on article by Dr Rossini and colleagues.
    Rico-Villademoros F; Saiz-Ruiz J
    J Clin Psychopharmacol; 2007 Feb; 27(1):98-9; author reply 99. PubMed ID: 17224727
    [No Abstract]   [Full Text] [Related]  

  • 10. T3 augmentation of SSRI resistant depression.
    Abraham G; Milev R; Stuart Lawson J
    J Affect Disord; 2006 Apr; 91(2-3):211-5. PubMed ID: 16483669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
    Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
    Higuchi H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
    Gothelf D; Rubinstein M; Shemesh E; Miller O; Farbstein I; Klein A; Weizman A; Apter A; Yaniv I
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1258-62. PubMed ID: 16292117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
    Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
    J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
    Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remarkable antidepressant augmentation effect of raloxifene, a selective estrogen receptor modulator, in a partial responder to fluvoxamine: a case report.
    Sugiyama N; Sasayama D; Amano N
    J Clin Psychiatry; 2007 Apr; 68(4):636-7. PubMed ID: 17474826
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital].
    Kostiukova EG; Granenov GM; Andreĭchik LA; Serditov OV; Mosolov SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(1):24-9. PubMed ID: 12616734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
    Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.